memantine and Dementia Praecox
memantine has been researched along with Dementia Praecox in 45 studies
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"To integrate all evidence derived from randomized controlled trials (RCTs) of both pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia (CRS)." | 9.41 | Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. ( Carvalho, AF; Chen, MH; Chu, CS; Correll, CU; Hsu, CW; Il Shin, J; Liang, CS; Stubbs, B; Thompson, T; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yeh, TC; Yu, CL, 2023) |
"Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia." | 9.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
"The uncompetitive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measures of auditory information processing in both healthy subjects (HS) and patients with schizophrenia." | 9.34 | Memantine effects on auditory discrimination and training in schizophrenia patients. ( Bhakta, SG; Clifford, RE; Joshi, YB; Kotz, J; Light, GA; Molina, JL; Roberts, BZ; Swerdlow, NR; Talledo, J; Thomas, ML, 2020) |
"This study shows that, add-on memantine would be helpful, in the adjunctive treatment of depressive, positive, negative and general symptoms in patients with schizophrenia." | 9.24 | The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. ( Maracy, MR; Mohammadian-Sichani, M; Omranifard, V; Rajabi, F, 2017) |
"In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 9.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
"In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | 9.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
"We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia." | 9.17 | Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013) |
"Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients." | 9.14 | Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. ( Belmonte-de-Abreu, PS; Berk, M; de Lucena, D; Dodd, S; Fernandes, BS; Gama, CS; Giglio, LF; Gomes, FA; Kunz, M; Lobato, MI; Medeiros, DW; Pedrini, M, 2009) |
"Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits." | 9.13 | Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008) |
"Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients." | 9.01 | Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. ( Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019) |
"This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia." | 8.98 | Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( Cai, DB; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, SB; Wang, YY; Xiang, YT; Yang, XH; Zheng, W, 2018) |
"We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics." | 7.85 | Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017) |
"We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy." | 7.80 | Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. ( John, JP; Lukose, A; Manjunath, S, 2014) |
" Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 7.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
"Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | 6.72 | Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
"To integrate all evidence derived from randomized controlled trials (RCTs) of both pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia (CRS)." | 5.41 | Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. ( Carvalho, AF; Chen, MH; Chu, CS; Correll, CU; Hsu, CW; Il Shin, J; Liang, CS; Stubbs, B; Thompson, T; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yeh, TC; Yu, CL, 2023) |
"Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia." | 5.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
"The uncompetitive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measures of auditory information processing in both healthy subjects (HS) and patients with schizophrenia." | 5.34 | Memantine effects on auditory discrimination and training in schizophrenia patients. ( Bhakta, SG; Clifford, RE; Joshi, YB; Kotz, J; Light, GA; Molina, JL; Roberts, BZ; Swerdlow, NR; Talledo, J; Thomas, ML, 2020) |
"This study shows that, add-on memantine would be helpful, in the adjunctive treatment of depressive, positive, negative and general symptoms in patients with schizophrenia." | 5.24 | The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. ( Maracy, MR; Mohammadian-Sichani, M; Omranifard, V; Rajabi, F, 2017) |
"In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 5.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
"In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | 5.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
"We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia." | 5.17 | Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013) |
"Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients." | 5.14 | Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. ( Belmonte-de-Abreu, PS; Berk, M; de Lucena, D; Dodd, S; Fernandes, BS; Gama, CS; Giglio, LF; Gomes, FA; Kunz, M; Lobato, MI; Medeiros, DW; Pedrini, M, 2009) |
"Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits." | 5.13 | Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008) |
"Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients." | 5.01 | Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. ( Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019) |
"Fifteen RCTs (n = 988) examining memantine (5-20 mg/day) as an adjunct treatment for schizophrenia (9 trials with 512 patients), bipolar disorder (3 trials with 319 patients), and MDD (3 trials with 157 patients) were analyzed." | 5.01 | Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. ( Cai, DB; He, SH; Ng, CH; Ning, YP; Peng, XJ; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W; Zhou, YL; Zhu, XM, 2019) |
"This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia." | 4.98 | Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( Cai, DB; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, SB; Wang, YY; Xiang, YT; Yang, XH; Zheng, W, 2018) |
"We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics." | 3.85 | Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017) |
" Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e." | 3.80 | Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014) |
"We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy." | 3.80 | Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. ( John, JP; Lukose, A; Manjunath, S, 2014) |
"Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist." | 2.72 | Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021) |
"Schizophrenia is a devastating psychiatric illness." | 2.41 | Imaging the glutamatergic system in vivo--relevance to schizophrenia. ( Bressan, RA; Pilowsky, LS, 2000) |
"Schizophrenia is a severe, disabling chronic disorder affecting approximately 1% of the population." | 1.37 | Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. ( Dedeurwaerdere, S; Langlois, X; Pemberton, D; Straetemans, R; Wintmolders, C, 2011) |
Research
Studies (45)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (22.22) | 29.6817 |
2010's | 27 (60.00) | 24.3611 |
2020's | 8 (17.78) | 2.80 |
Authors
Authors | Studies |
---|---|
Yeh, TC | 2 |
Correll, CU | 2 |
Yang, FC | 2 |
Chen, MH | 2 |
Tseng, PT | 2 |
Hsu, CW | 2 |
Carvalho, AF | 2 |
Stubbs, B | 2 |
Thompson, T | 2 |
Chu, CS | 2 |
Yu, CL | 2 |
Il Shin, J | 2 |
Yang, SN | 2 |
Tu, YK | 2 |
Liang, CS | 2 |
Schaefer, M | 2 |
Sarkar, S | 1 |
Theophil, I | 1 |
Leopold, K | 2 |
Heinz, A | 2 |
Gallinat, J | 1 |
Martin, ED | 1 |
Deardorff, OG | 1 |
Menditto, AA | 1 |
Sethi, S | 1 |
Hopkins, TM | 1 |
Li, H | 1 |
Xing, M | 1 |
Zhang, C | 1 |
Molina, JL | 2 |
Voytek, B | 1 |
Thomas, ML | 2 |
Joshi, YB | 3 |
Bhakta, SG | 3 |
Talledo, JA | 3 |
Swerdlow, NR | 6 |
Light, GA | 5 |
Vayısoğlu, S | 1 |
Karahan, S | 1 |
Anıl Yağcıoğlu, AE | 1 |
Kikuchi, T | 1 |
Talledo, J | 1 |
Kotz, J | 1 |
Roberts, BZ | 1 |
Clifford, RE | 1 |
Czarnecka, K | 1 |
Chuchmacz, J | 1 |
Wójtowicz, P | 1 |
Szymański, P | 1 |
Zhang, W | 1 |
Bhakta, S | 2 |
Kishi, T | 3 |
Matsuda, Y | 3 |
Iwata, N | 3 |
Zheng, W | 2 |
Li, XH | 1 |
Yang, XH | 2 |
Cai, DB | 2 |
Ungvari, GS | 2 |
Ng, CH | 2 |
Wang, SB | 1 |
Wang, YY | 1 |
Ning, YP | 2 |
Xiang, YT | 2 |
Omranifard, V | 1 |
Rajabi, F | 1 |
Mohammadian-Sichani, M | 1 |
Maracy, MR | 1 |
Koola, MM | 2 |
Sklar, J | 1 |
Davis, W | 1 |
Nikiforuk, A | 1 |
Meissen, JK | 1 |
Sawant-Basak, A | 1 |
Aaronson, ST | 2 |
Kozak, R | 1 |
Ikuta, T | 1 |
Veerman, S | 1 |
Schulte, P | 1 |
de Haan, L | 4 |
Kantrowitz, JT | 1 |
Dunn, W | 1 |
Vinogradov, S | 1 |
Sekar, S | 1 |
Grandjean, J | 1 |
Garnell, JF | 1 |
Willems, R | 1 |
Duytschaever, H | 1 |
Seramani, S | 1 |
Su, H | 1 |
Ver Donck, L | 1 |
Bhakoo, KK | 1 |
Uribe, E | 1 |
Fernández, L | 2 |
Pacheco, D | 1 |
Nayadoleni, N | 1 |
Eblen-Zajjur, A | 1 |
Zhu, XM | 1 |
Zhang, QE | 1 |
Zhou, YL | 1 |
He, SH | 1 |
Peng, XJ | 1 |
Rezaei, F | 1 |
Mohammad-Karimi, M | 1 |
Seddighi, S | 1 |
Modabbernia, A | 1 |
Ashrafi, M | 1 |
Salehi, B | 1 |
Hammidi, S | 1 |
Motasami, H | 1 |
Hajiaghaee, R | 1 |
Tabrizi, M | 1 |
Akhondzadeh, S | 1 |
Ene-Stroescu, V | 1 |
Nguyen, T | 1 |
Waiblinger, BE | 1 |
Buchanan, RW | 1 |
Pillai, A | 1 |
Aitchison, KJ | 1 |
Weinberger, DR | 1 |
Dickerson, FB | 1 |
Veerman, SR | 3 |
Schulte, PF | 3 |
Iasevoli, F | 1 |
Buonaguro, EF | 1 |
Sarappa, C | 1 |
Marmo, F | 1 |
Latte, G | 1 |
Rossi, R | 1 |
Eramo, A | 1 |
Tomasetti, C | 1 |
de Bartolomeis, A | 1 |
John, JP | 1 |
Lukose, A | 1 |
Manjunath, S | 1 |
Chou, HH | 1 |
Balvaneda, B | 1 |
Smith, JD | 1 |
Deijen, JB | 1 |
Mazinani, R | 1 |
Nejati, S | 1 |
Khodaei, M | 1 |
Fakhri, A | 1 |
Pakseresht, S | 1 |
Haghdoost, MR | 1 |
Hekmatkhah, N | 1 |
Torkashvand, M | 1 |
Ghorbanzadeh, B | 1 |
Lieberman, JA | 1 |
Papadakis, K | 1 |
Csernansky, J | 1 |
Litman, R | 1 |
Volavka, J | 1 |
Jia, XD | 1 |
Gage, A | 1 |
de Lucena, D | 2 |
Fernandes, BS | 2 |
Berk, M | 1 |
Dodd, S | 1 |
Medeiros, DW | 1 |
Pedrini, M | 1 |
Kunz, M | 2 |
Gomes, FA | 1 |
Giglio, LF | 1 |
Lobato, MI | 1 |
Belmonte-de-Abreu, PS | 2 |
Gama, CS | 3 |
Fries, GR | 1 |
Stertz, L | 1 |
Aguiar, B | 1 |
Pfaffenseller, B | 1 |
Dedeurwaerdere, S | 1 |
Wintmolders, C | 1 |
Straetemans, R | 1 |
Pemberton, D | 1 |
Langlois, X | 1 |
Kato, T | 1 |
Rands, GS | 1 |
Antunes, P | 1 |
Moser, C | 1 |
Hinzpeter, A | 1 |
Krebs, M | 1 |
Krivoy, A | 1 |
Weizman, A | 1 |
Laor, L | 1 |
Hellinger, N | 1 |
Zemishlany, Z | 1 |
Fischel, T | 1 |
Cerullo, MA | 1 |
Adler, CM | 1 |
Strakowski, SM | 1 |
Eliassen, JC | 1 |
Nasrallah, HA | 1 |
Nasrallah, AT | 1 |
Zdanys, K | 1 |
Tampi, RR | 1 |
Bressan, RA | 1 |
Pilowsky, LS | 1 |
Clinical Trials (8)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590] | Phase 3 | 24 participants (Actual) | Interventional | 2005-11-30 | Terminated | ||
Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616] | Phase 3 | 13 participants (Actual) | Interventional | 2004-04-30 | Terminated | ||
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia[NCT03860597] | Phase 4 | 42 participants (Actual) | Interventional | 2018-04-01 | Completed | ||
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial[NCT05944510] | Phase 4 | 72 participants (Anticipated) | Interventional | 2023-08-31 | Recruiting | ||
Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Patients Suffering From Depression and Schizophrenia[NCT05803447] | 120 participants (Actual) | Observational | 2016-09-01 | Completed | |||
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?[NCT02234752] | Phase 2 | 3 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Funding no longer available and PI no longer working at the institution) | ||
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study[NCT00757978] | Phase 4 | 22 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
"Gamma Auditory Steady-state Response (ASSR). The Primary Unit of Measure of Auditory Steady State Response (ASSR) is Gamma Evoked Power (γEP), Expressed as Microvolts-squared."
1 ms, 85 dB clicks were presented in 500 ms trains at a frequency of 40 Hz; 250 click trains were played (inter-train interval=0.5 s). EEG was continuously recorded with 64-channel BioSemi ActiveTwo system (sampling rate=2048 Hz). Data processed offline via Matlab, EEGlab, & BrainVision Analyzer. Continuous data were segmented relative to stimulus onset (-100 ms to 500 ms) & each epoch was baseline-corrected relative to 100 ms pre-stimulus interval. γEP was assessed based on first 100 artifact-free epochs at Fz. Averaged epochs across click trains were transformed into power spectrum via fast Fourier transform using a bin width of 2 Hz. 40 Hz power spectrum was averaged across 4 Hz band from 38-42 Hz. Data were analyzed by RM-ANOVA, with diagnosis as a between- & drug condition (placebo vs MEM) as a within-subject factor. Analyses revealed robust & time bin-independent effects of diagnosis & drug across 200-500 ms window & thus this interval was the focus of all subsequent analyses. (NCT03860597)
Timeframe: 7 and 14 days post baseline
Intervention | Microvolts-squared (Mean) | |
---|---|---|
Placebo | Memantine | |
Healthy Subjects: 20 mg Memantine 1st, Then Placebo | 0.14 | 0.23 |
Healthy Subjects: Placebo 1st, Then 20 mg Memantine | 0.14 | 0.23 |
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo | 0.07 | 0.06 |
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine | 0.08 | 0.09 |
Mismatch Negativity (MMN); Unit of Measure of MMN is Microvolts.
85 dB SPL stimuli were presented via Etymotic ER3-A insert earphones. A 4-tone auditory oddball paradigm with 82% standards & 18% deviant stimuli, differed from standard in pitch, duration, or both. A pseudorandomized sequence produced a minimum of 3 standard tones between each deviant stimulus. All tones had 5-ms rise/fall times presented with a fixed 500-ms stimulus onset asynchrony. Subjects viewed a silent movie & instructed to ignore auditory stimuli. EEG were continuously recorded at a sampling rate of 2048-Hz from 64 channels, using BioSemi ActiveTwo system & downsampled to 512-Hz. Deviant-minus-standard difference waves were generated for each deviant type & low-pass filtered (20-Hz zerophase shift, 24 dB/octave rolloff). MMN was computed as mean amplitude across 135-205 ms range for each deviant type in difference waveforms at electrode Fz. Data were analyzed by RM-ANOVA, with diagnosis as a between-subject factor, & drug condition (placebo vs MEM) as a within-subject factor. (NCT03860597)
Timeframe: 7 and 14 days post baseline
Intervention | microvolts (Mean) | |
---|---|---|
Placebo | Memantine | |
Healthy Subjects: 20 mg Memantine 1st, Then Placebo | -3.52 | -3.28 |
Healthy Subjects: Placebo 1st, Then 20 mg Memantine | -3.52 | -3.28 |
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo | -1.60 | -1.70 |
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine | -3.15 | -2.44 |
Prepulse Inhibition (PPI)
"PPI of the startle reflex is the automatic reduction in startle magnitude (assessed by EMG of orbicularis oculi) when a startling stimulus (40 ms 118 dB(A) noise burst; PULSE) is preceded (10-120 msec) by a weak stimulus (here a 20 msec burst 16 dB over background PREPULSE). A %PPI metric is calculated based on the relative startle magnitude on (PREPULSE + PULSE) trials vs. PULSE alone trials. Possible maximal inhibition is 100%; there is no maximal negative value of inhibition. There is no clear advantage or disadvantage for lower or higher %PPI values, though on average, schizophrenia patients demonstrate lower % values compared to matched healthy subjects. Day 1 was baseline testing: testing occurred, data was collected, but no intervention was given. There were two possible interventions: active (MEM 20 mg po) and placebo. One intervention was given on day 7 post baseline, the other intervention was given on day 14 post baseline, with order of intervention balanced." (NCT03860597)
Timeframe: 7 and 14 days post baseline
Intervention | % inhibition of startle (Mean) | |
---|---|---|
Placebo | Memantine | |
Healthy Subjects: 20 mg Memantine 1st, Then Placebo | 11.78 | 25.55 |
Healthy Subjects: Placebo 1st, Then 20 mg Memantine | 14.11 | 21.36 |
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo | 26.85 | 20.55 |
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine | 32.45 | 10.11 |
Change in Level of Cognition
The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are not known to provider. Overall composite scores are reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | units on a scale (Number) | ||||
---|---|---|---|---|---|
Baseline Participant 1 | Week 6 Participant 1 | Baseline Participant 2 | Week 6 Participant 2 | Baseline Participant 3 | |
Galantamine ER, Memantine XR | 48 | 48 | 32 | 25 | 9 |
Free Tryptophan (TRP)
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | µM (Mean) | ||||
---|---|---|---|---|---|
Baseline tryptophan Participant 1 | Week-6 tryptophan Participant 1 | Baseline tryptophan Participant 2 | Week-6 tryptophan Participant 2 | Baseline tryptophan Participant 3 | |
KP Metabolites Values | 51.94 | 55.72 | 32.17 | 24.96 | 35.07 |
KYN/TRP
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | AUC Ratio (Number) | ||||
---|---|---|---|---|---|
Baseline KYN/TRP Participant 1 | Week-6 KYN/TRP Participant 1 | Baseline KYN/TRP Participant 2 | Week-6 KYN/TRP Participant 2 | Baseline KYN/TRP Participant 3 | |
KP Metabolites Values | 1.21 | 1.31 | 1.06 | 0.8 | 0.79 |
KYNA/KYN
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | AUC Ratio (Number) | ||||
---|---|---|---|---|---|
Baseline KYNA/KYN Participant 1 | Week-6 KYNA/KYN Participant 1 | Baseline KYNA/KYN Participant 2 | Week-6 KYNA/KYN Participant 2 | Baseline KYNA/KYN Participant 3 | |
KP Metabolites Values | 0.075 | 0.050 | 0.121 | 0.114 | 0.152 |
Kynurenic Acid (KYNA)
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | MS* AUC (Mean) | ||||
---|---|---|---|---|---|
Baseline KYNA Participant 1 | Week-6 KYNA Participant 1 | Baseline KYNA Participant 2 | Week-6 KYNA Participant 2 | Baseline KYNA Participant 3 | |
KP Metabolites Values | 103911 | 83737 | 95139 | 73280 | 93163 |
Kynurenine (KYN)
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | µM (Mean) | ||||
---|---|---|---|---|---|
Baseline KYN Participant 1 | Week-6 KYN Participant 1 | Baseline KYN Participant 2 | Week-6 KYN Participant 2 | Baseline KYN Participant 3 | |
KP Metabolites Values | 1.62 | 1.85 | 0.86 | 0.71 | 0.76 |
PIC/KYN
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | AUC Ratio (Number) | ||||
---|---|---|---|---|---|
Baseline PIC/KYN Participant 1 | Week-6 PIC/KYN Participant 1 | Baseline PIC/KYN Participant 2 | Week-6 PIC/KYN Participant 2 | Baseline PIC/KYN Participant 3 | |
KP Metabolites Values | 0.0317 | 0.0175 | 0.1039 | 0.0989 | 0.0655 |
Picolinic Acid (PIC)
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
Intervention | MS* AUC (Mean) | ||||
---|---|---|---|---|---|
Baseline PIC Participant 1 | Week-6 PIC Participant 1 | Baseline PIC Participant 2 | Week-6 PIC Participant 2 | Baseline PIC Participant 3 | |
KP Metabolites Values | 44021 | 29542 | 81883 | 63745 | 40189 |
MATRICS Consensus Cognitive Battery Performance (MCCB)
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | standardized T-score (Mean) | |
---|---|---|
placebo | amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
Prepulse Inhibition (PPI)
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | % inhibition of startle (Mean) | |
---|---|---|
Placebo | Amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
Targeted Cognitive Training (TCT): PositScience, Inc.
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | msec (Mean) | |
---|---|---|
placebo | amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
Reviews
13 reviews available for memantine and Dementia Praecox
Article | Year |
---|---|
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch | 2023 |
Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Memantine; Psychiatri | 2019 |
Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Topics: Animals; Antipsychotic Agents; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Memanti | 2020 |
Memantine in neurological disorders - schizophrenia and depression.
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Clinical Trials as Topic; Depression | 2021 |
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Memantine; Psychiatric | 2018 |
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Topics: Auditory Perception; Cognitive Dysfunction; Excitatory Amino Acid Agonists; Excitatory Amino Acid An | 2018 |
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
Topics: Bipolar Disorder; Cognition; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combinat | 2019 |
Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials.
Topics: Antipsychotic Agents; Humans; Memantine; Randomized Controlled Trials as Topic; Receptors, N-Methyl- | 2013 |
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
Topics: Animals; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Memantine; Nootropic A | 2014 |
The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged.
Topics: Clozapine; Drug Delivery Systems; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitat | 2014 |
[Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
Topics: Alzheimer Disease; Binding Sites; Brain Ischemia; Dizocilpine Maleate; Humans; Magnesium; Memantine; | 2004 |
A systematic review of off-label uses of memantine for psychiatric disorders.
Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio | 2008 |
Imaging the glutamatergic system in vivo--relevance to schizophrenia.
Topics: Brain Chemistry; Humans; Ketamine; Memantine; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Gl | 2000 |
Trials
16 trials available for memantine and Dementia Praecox
Article | Year |
---|---|
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia.
Topics: Double-Blind Method; Electroencephalography; Excitatory Amino Acid Antagonists; Humans; Memantine; S | 2020 |
Memantine effects on auditory discrimination and training in schizophrenia patients.
Topics: Auditory Perception; Discrimination, Psychological; Double-Blind Method; Humans; Memantine; Receptor | 2020 |
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Auditory Perception; Chronic Disease; Cortical Synchronization; Cross-O | 2017 |
The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial.
Topics: Adult; Antipsychotic Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 2017 |
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Ky | 2018 |
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid A | 2013 |
Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Meth | 2016 |
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Drug Resistance; Drug Synergism; Drug | 2017 |
Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2017 |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B | 2016 |
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excit | 2009 |
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Bli | 2009 |
Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine Agents; Double-Blind Me | 2010 |
Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Cognition Disorders; Female; Humans; Inpatients; | 2008 |
Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.
Topics: Adult; Antipsychotic Agents; Dominance, Cerebral; Dopamine Agents; Double-Blind Method; Drug Therapy | 2007 |
Other Studies
16 other studies available for memantine and Dementia Praecox
Article | Year |
---|---|
Adjunct memantine for clozapine rechallenge following cardiomyopathy.
Topics: Antipsychotic Agents; Cardiomyopathies; Clozapine; Humans; Memantine; Schizophrenia | 2020 |
Antipsychotics-associated obsessive-compulsive symptoms: individualized treatments and clinical benefits of memantine: a case report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Memantine; Obsessive-Compulsive Disorder; Schizophrenia; | 2020 |
Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Humans; Memantine; Risperidone; Schizop | 2017 |
Response to the letter from Dr. Veerman and colleagues.
Topics: Antipsychotic Agents; Cognition; Humans; Memantine; Schizophrenia | 2017 |
Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Cognition; Humans; Memantine; Schizophrenia | 2017 |
Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.
Topics: Animals; Antipsychotic Agents; Auditory Perception; Humans; Learning; Memantine; Neuronal Plasticity | 2018 |
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; | 2019 |
Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.
Topics: Animals; Animals, Newborn; Auditory Cortex; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum | 2019 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato | 2014 |
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia.
Topics: Animals; Benzazepines; Brain; Carrier Proteins; Disks Large Homolog 4 Protein; Dopamine; Dopamine Ag | 2014 |
Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study.
Topics: Adult; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Psy | 2014 |
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituatio | 2016 |
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Biological Transport; Brain; B | 2011 |
Memantine as a neuroprotective treatment in schizophrenia.
Topics: Calcium; Glutamic Acid; Humans; Memantine; Neurons; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2005 |
[Memantine as an adjunctive therapy for schizophrenia negative symptoms].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Memantine; Middle Aged; Rece | 2005 |
Memantine-associated reversal of clozapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Clozapine; Dopamine Agents; Humans; Male; Memantine; N-Methylaspartate; | 2007 |